Large Scale Identification of Variant Proteins in Glioma Stem Cells

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift


Glioblastoma (GBM), the most malignant of primary brain tumors, is a devastating and deadly disease, with a median survival of 14 months from diagnosis, despite standard regimens of radical brain tumor surgery, maximal safe radiation, and concomitant chemotherapy. GBM tumors nearly always re-emerge after initial treatment and frequently display resistance to current treatments. One theory that may explain GBM re-emergence is the existence of glioma stemlike cells (GSCs). We sought to identify variant protein features expressed in low passage GSCs derived from patient tumors. To this end, we developed a proteomic database that reflected variant and nonvariant sequences in the human proteome, and applied a novel retrograde proteomic workflow, to identify and validate the expression of 126 protein variants in 33 glioma stem cell strains. These newly identified proteins may harbor a subset of novel protein targets for future development of GBM therapy.


Enheter & grupper
Externa organisationer
  • Virginia Commonwealth University
  • Washington University in St. Louis
  • New York University
  • University of Texas

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Cancer och onkologi
  • Läkemedelskemi


Sidor (från-till)73-79
Antal sidor7
TidskriftACS Chemical Neuroscience
StatusPublished - 2018 jan 17
Peer review utfördJa